News · 26 weeks34-83%
2026-04-192026-10-11
Mix2190d
- Insider10(48%)
- SEC Filings6(29%)
- Earnings2(10%)
- Leadership2(10%)
- Other1(5%)
Latest news
25 items- SECSEC Form 8-K filed by Azenta Inc.8-K - Azenta, Inc. (0000933974) (Filer)
- INSIDERInterim CEO Madaus Martin D covered exercise/tax liability with 1,456 units of Common, decreasing direct ownership by 3% to 42,602 units (SEC Form 4) (for withholding tax)4 - Azenta, Inc. (0000933974) (Issuer)
- SECAzenta Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Azenta, Inc. (0000933974) (Filer)
- INSIDERInterim CEO Madaus Martin D was granted 36,653 units of Common, increasing direct ownership by 495% to 44,058 units (SEC Form 4)4 - Azenta, Inc. (0000933974) (Issuer)
- INSIDERPresident Multiomics Martin William E. Iii was granted 15,272 units of Common, increasing direct ownership by 86% to 33,062 units (SEC Form 4)4 - Azenta, Inc. (0000933974) (Issuer)
- INSIDERSVP and CHRO Pirogova Olga was granted 15,272 units of Common, increasing direct ownership by 48% to 47,225 units (SEC Form 4)4 - Azenta, Inc. (0000933974) (Issuer)
- INSIDEREVP, CFO and Treasurer Lin Lawrence Y. was granted 30,544 units of Common, increasing direct ownership by 38% to 110,199 units (SEC Form 4)4 - Azenta, Inc. (0000933974) (Issuer)
- INSIDERSVP, Gen Counsel & Secretary Starr Ephraim was granted 15,272 units of Common, increasing direct ownership by 22% to 84,000 units (SEC Form 4)4 - Azenta, Inc. (0000933974) (Issuer)
- INSIDERVP Chief Accounting Officer Bello Erik J. was granted 4,586 units of Common (SEC Form 4)4 - Azenta, Inc. (0000933974) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bello Erik J.3 - Azenta, Inc. (0000933974) (Issuer)
- SECAzenta Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Azenta, Inc. (0000933974) (Filer)
- PRAzenta Receives Full Repayment of $35 Million Vendor Loan Related to Sale of B Medical SystemsBURLINGTON, Mass., Sept. 4, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has received repayment in full, prior to maturity, of the $35 million secured vendor loan extended in connection with the previously announced sale of B Medical Systems S.à r.l. to Thelema S.à r.l.As part of the transaction, which closed on July 1, 2026, Azenta Germany GmbH, a wholly owned subsidiary of Azenta, Inc., entered into a Vendor Loan Agreement with Thelema S.à r.l., pursuant to which Azenta Germany GmbH provided a secured term loan to Thelema S.à r.l. in an aggregate principal amount of $35 million. The vendor loan, which was secured by a pledge over the equity interests of B Medical
- SECAzenta Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Azenta, Inc. (0000933974) (Filer)
- PRAZENTA ANNOUNCES LEADERSHIP TRANSITIONCurrent Director Dr. Martin Madaus Appointed Interim CEOCompany Reaffirms Previously Announced Fourth Quarter Fiscal 2026 Total Revenue GuidanceBURLINGTON, Mass., Aug. 24, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company") today announced that current member of the Board of Directors (the "Board") Dr. Martin Madaus has been appointed interim President and CEO, and that John Marotta has resigned as an executive officer and director of the Company.Dr. Madaus has served in multiple CEO roles in the diagnostics and life science tools industry and joined the Azenta Board in 2024 – making him the ideal individual to lead the Company during this transition. He is a Senior O
- INSIDERSVP and CHRO Pirogova Olga covered exercise/tax liability with 1,085 units of Common, decreasing direct ownership by 3% to 31,953 units (SEC Form 4) (tax withholding)4 - Azenta, Inc. (0000933974) (Issuer)
- SECSEC Form 10-Q filed by Azenta Inc.10-Q - Azenta, Inc. (0000933974) (Filer)
- INSIDERSVP, Gen Counsel & Secretary Starr Ephraim bought $8,096 worth of Common (335 units at $24.17), increasing direct ownership by 0.49% to 68,728 units (SEC Form 4)4 - Azenta, Inc. (0000933974) (Issuer)
- SECAzenta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Azenta, Inc. (0000933974) (Filer)
- PRAzenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026.BURLINGTON, Mass., Aug. 4, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the third quarter ended June 30, 2026. The results of B Medical Systems are reported as discontinued operations and reflected in total diluted EPS. The Company entered into a definitive agreement to sell the business during fiscal 2025, and the transaction closed on July 1, 2026, on the terms described in the Company's Current Report on Form 8-K filed on July 8, 2026. Quarter EndedDollars in millions, except per share dataJune 30,March 31,June 30,Change202620262025(1)Prior QtrPrior Yr.Revenue from Continuing Operations$ 161$ 145$ 14411 %12 %Organic growth9 %Sampl
- PRCabot Corporation Announces Planned Leadership TransitionBOSTON, July 30, 2026 (GLOBE NEWSWIRE) -- Cabot Corporation (NYSE:CBT) announced today that Sean Keohane has notified the Board of Directors of his decision to retire as President and Chief Executive Officer (CEO) of the Company and to step down from the Company’s Board of Directors, each effective September 30, 2026. Erica McLaughlin, Executive Vice President, Chief Financial Officer (CFO) and Head of Corporate Strategy, has been elected to succeed Keohane as President and CEO, and to serve on the Board as a member of the class of directors whose term expires at the 2029 Annual Meeting of Stockholders, both effective October 1, 2026. Keohane will remain with the Company in an advisory ca
- PRAzenta Announces Fiscal 2026 Third Quarter Conference Call and WebcastBURLINGTON, Mass., July 22, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal third quarter 2026 earnings which ended on June 30, 2026, on Tuesday, August 4, 2026, after the market closes.The Company will host a conference call and live webcast to discuss its financial results the following day, Wednesday, August 5, 2026, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on August 6, 2026.About Azenta Life SciencesAzenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling i
- SECAzenta Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Azenta, Inc. (0000933974) (Filer)
- PRAzenta Completes Sale of B Medical SystemsBURLINGTON, Mass., July 8, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced the completion of the previously disclosed sale of its B Medical Systems business to Thelema S.à r.l.The transaction was originally announced on December 29, 2025 and closed on July 1, 2026 following the satisfaction of all closing conditions. Under the terms of the agreement, Azenta sold B Medical Systems for a fixed purchase price of $63 million in cash, of which $35 million was funded through a short-term secured vendor loan from an Azenta subsidiary to Thelema. Additional details regarding the transaction are available in the Company's Current Report on Form 8-K filed with the Securities and Exchan
- SECSEC Form SD filed by Azenta Inc.SD - Azenta, Inc. (0000933974) (Filer)
- PRAzenta Publishes 2025 Environmental, Social, and Governance (ESG) ReportBURLINGTON, Mass., May 21, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, demonstrating continued progress against its key ESG priorities. The report includes ESG data for the Company's fiscal year ended September 30, 2025.The report offers a comprehensive overview of the Company's ESG approach, highlighting achievements across three core pillars:Environmental Protection: We understand the broad scope of our operations and are committed to reducing our environmental impact while continuing to expand our business.Social Impact: We are committed to making a positive impact on society, particularl
AZTA FAQ
6 questionsWhat does Azenta Inc. do?
Azenta, Inc. provides manufacturing automation solutions for the semiconductor industry, and life science sample-based services and solutions for the life sciences market worldwide. The company operates in two segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated ultra-cold storage systems and consumables, including racks, tubes, caps, plates, and foils; instruments, such as labeling, bar coding, capping, de-capping, auditing, sealing, peeling, piercing tubes, and plates. The Life Sciences Services segment offers genomic services and...Where does AZTA stock trade?
Azenta Inc. (AZTA) is listed on NASDAQ.What sector and industry is AZTA in?
Azenta Inc. operates in the Technology sector, Industrial Machinery/Components industry.What are analysts saying about AZTA?
Azenta Inc. has had 8 recent analyst actions on file. The most recent action was from Evercore ISI: Outperform on 2026-01-05. Recent price targets range from $3500.00 to $4400.00.What companies are similar to AZTA?
Notable peers in the same industry include ASML (ASML Holding N.V. New York Registry Shares), LRCX (Lam Research Corporation), TMO (Thermo Fisher Scientific Inc), DE (Deere & Company), DHR (Danaher Corporation). Compare AZTA side-by-side with any of them on Quantisnow.How can I track AZTA on Quantisnow?
Quantisnow aggregates Azenta Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AZTA to receive live email and push alerts on every new disclosure.